Display options
Share it on

Ann Surg Treat Res. 2015 Sep;89(3):145-50. doi: 10.4174/astr.2015.89.3.145. Epub 2015 Aug 24.

De novo hepatitis B virus infection developing after liver transplantation using a graft positive for hepatitis B core antibody.

Annals of surgical treatment and research

Jae Hyun Han, Dong Goo Kim, Gun Hyung Na, Eun Young Kim, Soo Ho Lee, Tae Ho Hong, Young Kyoung You, Jong Young Choi, Seung Kew Yoon

Affiliations

  1. Department of Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea.
  2. Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea.

PMID: 26366384 PMCID: PMC4559617 DOI: 10.4174/astr.2015.89.3.145

Abstract

PURPOSE: The use of hepatitis B core antibody (HBcAb)-positive grafts is increasing, especially where hepatitis B is endemic. However, this remains controversial because of the risk of development of de novo HBV infection.

METHODS: We collected information obtained between January 2000 and December 2012 and retrospectively analyzed data on 187 HBsAg-negative donors and recipients were analyzed retrospectively. De novo HBV infection was defined as development of HBsAg positivity with or without detection of HBV DNA.

RESULTS: Forty patients (21.4%) received HBcAb-positive grafts. Survival rate did not differ by donor HBcAb status (P = 0.466). De novo HBV infection occurred in five patients (12.5%) who were not treated with anti-HBV prophylaxis, and was significantly more prevalent in hepatitis B surface antibody (HBsAb)- and HBcAb-negative than HBsAb- and HBcAb-positive recipients (50% vs. 4.2%, P = 0.049). All patients except one were treated with entecavir with/without antihepatitis B immunoglobulin and four were negative in terms of HBV DNA seroconversion. No patient died.

CONCLUSION: HBcAb-positive grafts are safe without survival difference. However, the risk of de novo hepatitis B virus infection was significantly increased in HBsAb- and HBcAb-negative recipients. All patients were successfully treated even after recurrence.

Keywords: Hepatitis B antibodies; Liver transplantation; Prognosis; de novo hepatitis B

References

  1. Liver Transpl. 2001 Jan;7(1):51-8 - PubMed
  2. Transplant Proc. 2004 Apr;36(3):520-2 - PubMed
  3. Transpl Int. 2011 Jun;24(6):570-81 - PubMed
  4. Transplantation. 2013 Apr 15;95(7):960-5 - PubMed
  5. Transplant Proc. 2007 Jun;39(5):1488-90 - PubMed
  6. J Hepatol. 2013 Apr;58(4):715-23 - PubMed
  7. Transplantation. 2003 Feb 15;75(3 Suppl):S45-8 - PubMed
  8. Am J Gastroenterol. 2004 Apr;99(4):767-8 - PubMed
  9. Transplant Proc. 1993 Apr;25(2):1755-7 - PubMed
  10. Clin Transplant. 2000;14 Suppl 2:20-4 - PubMed
  11. J Hepatol. 1997 Mar;26(3):517-26 - PubMed
  12. Liver Transpl Surg. 1997 Mar;3(2):105-11 - PubMed
  13. Clin Transplant. 2011 May-Jun;25(3):E243-9 - PubMed

Publication Types